CFB
GPCR icon

Cullen/Frost Bankers’s Structure Therapeutics GPCR Stock Holding History

Cullen/Frost Bankers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429 Hold
8
– – ﹤0.01% 1355
2026
Q1 		$386 Hold
8
– – ﹤0.01% 1336
2025
Q4 		$556 Hold
8
– – ﹤0.01% 1342
2025
Q3 		$224 Hold
8
– – ﹤0.01% 1300
2025
Q2 		$166 Hold
8
– – ﹤0.01% 1286
2025
Q1 		$138 Hold
8
– – ﹤0.01% 1271
2024
Q4 		$217 Hold
8
– – ﹤0.01% 1317
2024
Q3 		$351 Hold
8
– – ﹤0.01% 1190
2024
Q2 		$314 Buy
+8
New +$328 ﹤0.01% 1217

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cullen/Frost Bankers's GPCR Position: Q2 2026 in Review

Cullen/Frost Bankers held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 8 shares worth $429. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Cullen/Frost Bankers first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $556 in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Cullen/Frost Bankers held 8 shares of Structure Therapeutics worth $429 as of Q2 2026.
  • Cullen/Frost Bankers left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1355 holding.
  • Cullen/Frost Bankers first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Cullen/Frost Bankers's Structure Therapeutics position peaked at $556 in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.